Skip to Content
Merck
All Photos(2)

Documents

Safety Information

41326

Supelco

Clofibrate

analytical standard

Synonym(s):

2-(4-Chlorophenoxy)-2-methylpropionic acid ethyl ester, Ethyl 2-(4-chlorophenoxy)-2-methylpropionate, Ethyl 2-(4-chlorophenoxy)isobutyrate

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C12H15ClO3
CAS Number:
637-07-0
Molecular Weight:
242.70
Beilstein:
1913459
EC Number:
211-277-4
MDL number:
MFCD00000615
UNSPSC Code:
77101502
PubChem Substance ID:
329756088
NACRES:
NA.24

grade

analytical standard

Quality Level

100

Assay

≥99.0% (GC)

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

refractive index

n20/D 1.502-1.504

application(s)

forensics and toxicology
pharmaceutical (small molecule)

format

neat

SMILES string

CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1

InChI

1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3

InChI key

KNHUKKLJHYUCFP-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Recommended products

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Pictograms

CorrosionExclamation mark
GHS05,GHS07

Signal Word

Danger

Hazard Statements

H302,H315,H318,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

235.4 °F - closed cup

Flash Point(C)

113 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

FSL

Group 4: Flammable liquids
Type 3 petroleums
Hazardous rank III
Water insoluble liquid

JAN Code

41326-BULK:
41326-VAR:
41326-100MG:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCL4805
BCCK3724
BCCH5625
BCCB8431
BCBV7245

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Clofibrate.
IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, 24, 39-58 (1980-01-01)
[Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate].
L M Dobordzhginidze et al.
Kardiologiia, 44(2), 96-103 (2004-05-06)
Tao Xiong et al.
Indian pediatrics, 49(1), 35-41 (2012-02-10)
To evaluate the effect of clofibrate for unconjugated hyperbilirubinemia in neonates. A systematic review with meta-analysis of randomized controlled trials or quasi-randomized controlled trials was conducted to evaluate the clofibrate treatment in neonates with unconjugated hyperbilirubinemia. We followed the guidelines
S Oikawa et al.
Nihon rinsho. Japanese journal of clinical medicine, 52(12), 3285-3291 (1994-12-01)
Clofibrate has cholesterol- and triglyceride-lowering effect. They affect on the various points in the metabolic pathway of lipoproteins. They improve VLDL-synthesis in liver and increase the activity of LPL and hepatic TG lipase. As the results, HDL-cholesterol increases and LDL
G Calais et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 22(2), 99-103 (1991-10-01)
It is generally accepted that hypoxia is a common occurrence in many experimental and human tumours and that it is a major cause of local failure after radiotherapy. Many attempts have been made over the last years to eliminate this
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service